

Diagnosis and Management of Immune Related Adverse Events (irAEs)



Diagnosis and General Management

Early recognition and **prompt intervention** are **critical** to successful management of irAEs.^{1,2}



Early involvement of multidisciplinary team: physicians, nurses, pharmacists.^{1,2}



Exercise caution, as any new symptoms that arise may be related to irAEs.^{1,2}



Patient and caregiver education is critical.^{1,2}



Dose reductions of immune checkpoint inhibitors (ICPIs) are **not recommended**



Consult with **relevant specialty services** (eg, dermatology, endocrinology) in a timely manner.^{1,2}

Instead, **permanent discontinuation** or **treatment interruption** are recommended, as appropriate.^{1,2}

Commonly Used Guidelines

Society

Guidelines for Management of ICPI-associated irAEs

American Society of Clinical Oncology (ASCO)

Brahmer et al. J Clin Oncol. 2018;36(17):1714-1768. DOI: <https://doi.org/10.1200/JCO.2017.77.6385>

National Comprehensive Cancer Network (NCCN®)

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Management of Immunotherapy-Related Toxicities. V.1.2021 Available at: nccn.org

The Society for Immunotherapy of Cancer (SITC)

Puzanov et al. J Immunother Cancer. 2017;5(1):95 DOI: <https://doi.org/10.1186/s40425-017-0300-z>

European Society for Medical Oncology (ESMO)

Haanen et al. Ann Oncol. 2017;28(4):iv119-iv142 Available at: <https://doi.org/10.1093/annonc/mdx225>

Patients and Caregivers



Education Guideline Recommendations

Provide ICPI-specific information to patients and caregivers before initiating therapy^{1,3}

Continued patient and caregiver education throughout treatment and survivorship¹

IO Wallet Card

The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer.¹ Available at:

https://www.ons.org/sites/default/files/2019-01/IO%20Card%201-sided_Vertical.pdf

Patient management KEY QUESTIONS

- Have you ever received an ICPI/immunotherapy?
 - ✓ irAEs can occur after discontinuation of ICPIs³
- Do you have an immunotherapy wallet card?
 - ✓ Wallet cards list the type of immunotherapy, key symptoms, and how to notify HCPs¹
- Do you have an autoimmune condition?
 - ✓ ICPIs may exacerbate preexisting autoimmune conditions^{4,5}

References: 1. Brahmer et al. J Clin Oncol. 2018;36(17):1714-1768; 2. Puzanov et al. J Immunother Cancer. 2017;5(1):95. 3. Postow et al. N Engl J Med. 2018;378(2):158-68 4. Menzies et al. Ann Oncol. 2017;28:368; 5. Johnson et al. JAMA Oncol. 2016;2:234

This response is not intended to offer recommendations for administering GSK products in a manner inconsistent with approved labeling. In order for GSK to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 888-825-5249. Trademarks are property of their respective owners.